- Home
- ICLK vs TNXP Comparison
ICLK vs TNXP Comparison
Compare ICLK & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICLK
- TNXP
- Stock Information
- Founded
- ICLK 2009
- TNXP 2007
- Country
- ICLK Hong Kong
- TNXP United States
- Employees
- ICLK N/A
- TNXP N/A
- Industry
- ICLK Computer Software: Prepackaged Software
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- ICLK Technology
- TNXP Health Care
- Exchange
- ICLK Nasdaq
- TNXP Nasdaq
- Market Cap
- ICLK 70.9M
- TNXP 71.6M
- IPO Year
- ICLK 2017
- TNXP N/A
- Fundamental
- Price
- ICLK $7.70
- TNXP $9.17
- Analyst Decision
- ICLK
- TNXP Strong Buy
- Analyst Count
- ICLK 0
- TNXP 2
- Target Price
- ICLK N/A
- TNXP $5,350.00
- AVG Volume (30 Days)
- ICLK 57.0K
- TNXP 1.8M
- Earning Date
- ICLK 11-27-2024
- TNXP 03-31-2025
- Dividend Yield
- ICLK N/A
- TNXP N/A
- EPS Growth
- ICLK N/A
- TNXP N/A
- EPS
- ICLK N/A
- TNXP N/A
- Revenue
- ICLK $130,443,999.00
- TNXP $11,291,000.00
- Revenue This Year
- ICLK $26.49
- TNXP $64.71
- Revenue Next Year
- ICLK $12.11
- TNXP $24.49
- P/E Ratio
- ICLK N/A
- TNXP N/A
- Revenue Growth
- ICLK N/A
- TNXP 183.05
- 52 Week Low
- ICLK $1.03
- TNXP $9.03
- 52 Week High
- ICLK $11.38
- TNXP $1,248.00
- Technical
- Relative Strength Index (RSI)
- ICLK 42.86
- TNXP 33.86
- Support Level
- ICLK $7.85
- TNXP $11.18
- Resistance Level
- ICLK $8.26
- TNXP $12.42
- Average True Range (ATR)
- ICLK 0.59
- TNXP 2.56
- MACD
- ICLK -0.14
- TNXP -0.84
- Stochastic Oscillator
- ICLK 14.12
- TNXP 0.82
About ICLK iClick Interactive Asia Group Limited
iClick Interactive Asia Group Ltd is an enterprise and marketing cloud Platform in China. It offers a consumer full lifecycle solution that addresses client's needs from traffic acquisition, customer relations management, and business decision optimization driven by data analytics in the retail era. It has two operating segments: Marketing Solutions, and Enterprise Solutions. Geographically, it derives the majority revenue from Mainland China and also has a presence in Hong Kong and other countries.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.